Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 6/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.74 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.74 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.74 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.74 |
| ▸ | IGF1R | P08069 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 4/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pipratecol SCHEMBL31419979 | 1.00 | ADRA1D (0.74) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| Pipratecol SCHEMBL29623033 | 1.00 | ADRA1D (0.74) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL11389287 | 0.86 | ADRA1D (0.84) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL11397149 | 0.86 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| SCHEMBL11388425 | 0.86 | ADRA1D (0.98) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL11396812 | 0.85 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| SCHEMBL8442587 | 0.85 | IGF1R (0.81) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL8442876 | 0.84 | IGF1R (0.80) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL9019641 | 0.84 | IGF1R (0.80) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| SCHEMBL27959881 | 0.83 | IGF1R (1.00) | ADRA1DADRA1AADRA1BADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | claimed |
| EP-4106816-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | North Atlantic Holdings LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220387343-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2022-12-08 | — | — | US | claimed |
| US-11446257-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2022-09-20 | — | — | US | claimed |
| US-8354116-B2 | Bifunctional synthetic molecules | BIOCHEMICS, INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101820886-A | Bifunctional synthetic molecules | BIOCHEMICS INC | 2010-09-01 | — | — | CN | claimed |
| EP-2167104-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BioChemics, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2008156758-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BIOCHEMICS, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-20080312296-A1 | Bifunctional synthetic molecules | ADEC PRIVATE EQUITY INVESTMENTS, LLC | 2008-12-18 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312296-A1 | Bifunctional synthetic molecules | PGF, VEGFA, PTGFR | ADRA1D 1150/4885ADRA1A 1447/4885ADRA1B 1816/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | ADRA1D 94/4885ADRA1A 159/4885ADRA1B 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.